BRPI0918593B8 - composição farmacêutica para uso no tratamento de infecções sexualmente transmitidas - Google Patents

composição farmacêutica para uso no tratamento de infecções sexualmente transmitidas

Info

Publication number
BRPI0918593B8
BRPI0918593B8 BRPI0918593A BRPI0918593A BRPI0918593B8 BR PI0918593 B8 BRPI0918593 B8 BR PI0918593B8 BR PI0918593 A BRPI0918593 A BR PI0918593A BR PI0918593 A BRPI0918593 A BR PI0918593A BR PI0918593 B8 BRPI0918593 B8 BR PI0918593B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
sexually transmitted
transmitted infections
treatment
pharmaceutically acceptable
Prior art date
Application number
BRPI0918593A
Other languages
English (en)
Inventor
Arzola Paniagua Angélica
Barranco Hernández Gustavo
Pablo Senosiain Peláez Juan
García Salgado López Raùl
Original Assignee
Laboratorios Senosiain S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41796784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0918593(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Senosiain S A De C V filed Critical Laboratorios Senosiain S A De C V
Publication of BRPI0918593A2 publication Critical patent/BRPI0918593A2/pt
Publication of BRPI0918593A8 publication Critical patent/BRPI0918593A8/pt
Publication of BRPI0918593B1 publication Critical patent/BRPI0918593B1/pt
Publication of BRPI0918593B8 publication Critical patent/BRPI0918593B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composição farmacêutica para uso no tratamento de infecções sexualmente transmitidas a presente invenção refere-se a uma composição farmacêutica oral sólida que compreende fluconazol, tinidazol e clindamicina ou um sal farmaceuticamente aceitável do mesmo, em que farmaceuticamente aceitáveis é o teor de excipientes significativamente mais baixo do que o teor dos princípios ativos, o uso da composição para administração oral com atividade terapêutica para tratar infecções sexualmente transmitidas.
BRPI0918593A 2008-09-04 2009-09-04 composição farmacêutica para uso no tratamento de infecções sexualmente transmitidas BRPI0918593B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MX2008011321A MX2008011321A (es) 2008-09-04 2008-09-04 Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual.
MXMX/A/2008/011321 2008-09-04
PCT/IB2009/006738 WO2010026469A1 (es) 2008-09-04 2009-09-04 Composición farmacéutica para el uso en el tratamiento de infecciones de transmisión sexual

Publications (4)

Publication Number Publication Date
BRPI0918593A2 BRPI0918593A2 (pt) 2018-05-22
BRPI0918593A8 BRPI0918593A8 (pt) 2018-12-11
BRPI0918593B1 BRPI0918593B1 (pt) 2020-11-10
BRPI0918593B8 true BRPI0918593B8 (pt) 2021-05-25

Family

ID=41796784

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918593A BRPI0918593B8 (pt) 2008-09-04 2009-09-04 composição farmacêutica para uso no tratamento de infecções sexualmente transmitidas

Country Status (13)

Country Link
US (1) US20110166087A1 (pt)
EP (1) EP2329819B1 (pt)
KR (1) KR101653424B1 (pt)
BR (1) BRPI0918593B8 (pt)
CA (1) CA2735926C (pt)
CO (1) CO6321156A2 (pt)
EC (1) ECSP11010941A (pt)
ES (1) ES2734280T3 (pt)
HN (1) HN2011000661A (pt)
MX (1) MX2008011321A (pt)
PE (1) PE20110448A1 (pt)
UY (1) UY32091A (pt)
WO (1) WO2010026469A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113768883A (zh) * 2021-08-25 2021-12-10 海南海神同洲制药有限公司 一种高稳定性盐酸克林霉素棕榈酸酯颗粒的制备方法
CN113768885A (zh) * 2021-09-16 2021-12-10 海南海神同洲制药有限公司 一种伏立康唑干混悬剂的制备工艺
CN114306209A (zh) * 2022-01-10 2022-04-12 江苏远恒药业有限公司 一种替硝唑栓的组合物及其制备方法与应用
CN116251067B (zh) * 2023-04-23 2024-06-07 淄博市中心医院 一种氟康唑片、制备方法及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094431B2 (en) 2000-10-12 2006-08-22 Mickey L. Peshoff Method of healing skin wounds in mammals and a composition therefor
MXPA02007641A (es) * 2002-08-08 2004-04-02 Alparis Sa De Cv Uso de farmaceutico de la combinacion de fluconazol-tinidazol y su composicion para la administracion oral.
US8309103B2 (en) 2004-01-22 2012-11-13 Alparis, S.A. De C.V. Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage
CA2635994A1 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Drug delivery system for bioadhesion to a vulvovaginal surface
WO2008005783A2 (en) * 2006-06-30 2008-01-10 Drugtech Corporation Treatment of non- infectious inflammatory vulvovaginitis with a bioadhesive clindamycin composition

Also Published As

Publication number Publication date
MX2008011321A (es) 2010-03-04
KR20110050678A (ko) 2011-05-16
BRPI0918593B1 (pt) 2020-11-10
BRPI0918593A2 (pt) 2018-05-22
CA2735926C (en) 2016-09-06
WO2010026469A1 (es) 2010-03-11
US20110166087A1 (en) 2011-07-07
BRPI0918593A8 (pt) 2018-12-11
EP2329819A4 (en) 2011-09-14
UY32091A (es) 2010-02-26
ECSP11010941A (es) 2011-06-30
CO6321156A2 (es) 2011-09-20
CA2735926A1 (en) 2010-03-11
EP2329819B1 (en) 2019-05-01
HN2011000661A (es) 2013-09-16
EP2329819A1 (en) 2011-06-08
ES2734280T3 (es) 2019-12-05
PE20110448A1 (es) 2011-07-20
KR101653424B1 (ko) 2016-09-01

Similar Documents

Publication Publication Date Title
BRPI0708640A8 (pt) composição farmacêutica, e, métodos para tratar um paciente com dor de cabeça de enxaqueca, para tratar um paciente com dor e para tratar um paciente com enxaqueca
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
BR112014014181A2 (pt) combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
BR112013003677A2 (pt) uso de agente farmacologicamente ativo e forma de dosagem farmacêutica
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BR112012028651A2 (pt) heterociclilbenzilpirazóis substituídos e uso do mesmo
BRPI0512311A (pt) uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas
WO2009037583A3 (en) Compositions and methods for treatment and prevention of osteoarthritis
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
BRPI0510449A (pt) uso de formulações de meloxicam em medicina veterinária
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
RU2011148355A (ru) Применение аллопуринола для ладонно-родошвенного синдрома
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
BR112018072177A2 (pt) composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
Oranje Recent developments in the management of common childhood skin infections
BRPI0918593A2 (pt) composição farmacêutica para uso no tratamento de infecções transmitidas sexualmente
BR112015029709A2 (pt) dihidroetorfina para o fornecimento de alívio da dor e anestesia
BR112012028652A2 (pt) hidroxialquilbenzilpirazois e seu uso
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
BR112016014903A8 (pt) combinações farmacêuticas que compreendem um inibidor de pi3k, seu uso, sua preparação combinada, e embalagem comercial

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2790 DE 25-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.